← Back to Search

CAR T-cell Therapy

agenT-797 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by MiNK Therapeutics

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 12 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new immune cell therapy called agenT-797 in patients whose solid tumors have come back or didn't respond to other treatments. The therapy uses special immune cells from a donor to help the patient's body fight the cancer.

Eligible Conditions

Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cell Therapy

Number Of Participants With Treatment-emergent Adverse Events (TEAEs)

Number Of TEAEs By The Dose Of iNKT Cell Therapy

+1 more

Secondary study objectives

Duration Of Response (DOR)

Objective Response Rate (ORR)

Persistence Of agenT-797 In Peripheral Blood Samples

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Part 2: agenT-797 in Combination with approved ICIsExperimental Treatment2 Interventions

Single prespecified dose of agenT-797 administered by IV infusion in combination with approved ICIs administered in accordance with manufacturer instructions and institutional guidelines as per standard of care

Group II: Part 1: Monotherapy with agenT-797Experimental Treatment1 Intervention

3+3 Dose escalation of agenT-797 will be administered as a single intravenous (IV) infusion.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

agenT-797

2022

Completed Phase 2

~70

Approved ICIs

2022